Fungal infections as complication of monoclonal antibody therapy directed against IL-17 mediated inflammation: estimating incidence and severity and identifying influence of immunogenetics to establish a guideline for screening, prevention and treatment.

Fungal infections as complication of monoclonal antibody therapy directed against IL-17 mediated inflammation: estimating incidence and severity and identifying influence of immunogenetics to establish a guideline for screening, prevention and treatment. - Fungal infections as complication of anti-Th17 mAB therapy.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46165

Enrollment

100

Registered

2018-03-05

Start date

2018-10-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fungal infections inflammatory skin disease

Interventions

anti-Th17 mAb therapy

fungal infections

IL-17 pathway

psoriasis

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Diagnosis of psoriasis * Age * 18 years * Treatment with either a TNF-*-inhibitor for at least 1 year, ustekinumab for at least 1 year, secukinumab for at least 6 months, ixekizumab for at least 6 months or brodalumab for at least 6 months or planning to start treatment with an anti-Th17 mAb therapeutic agent * Registration in the BioCAPTURE registry

Exclusion criteria

Exclusion criteria: * Pregnancy * Any active cancer treatment

Design outcomes

Primary

Measure	Time frame
1) Incidence and severity of fungal infections. 2) Function immune system. 3) Mycobiome/microbiome. 4) Gene polymorphisms at DNA level.	—

Secondary

Measure	Time frame
non applicable	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)